Who
Jiandong Xu
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Estrella Immunopharma; 10% owner, Denali Capital Acquisition.
In numbers
- Trades disclosed
- 15
- Buys
- 4
- Sells
- 0
- Bought
- $5.1M
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 11 Apr 2022
- Last trade
- 18 Aug 2026
- Last filed
- 25 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Aug 2026filed 25 Aug 2026 | ESLA Estrella ImmunopharmaBiotechnology | SEC FORM 4 Code M | $82K100,000 at $0.815 | filing |
| 18 Aug 2026filed 25 Aug 2026 | ESLA Estrella Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —100,000 | filing |
| 18 Aug 2026filed 25 Aug 2026 | ESLA Estrella Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —100,000 | filing |
| 18 Aug 2026filed 25 Aug 2026 | ESLA Estrella ImmunopharmaBiotechnology | SEC FORM 4 Code M | $82K100,000 at $0.82 | filing |
| 7 Oct 2025filed 29 Apr 2026 | ESLA Estrella ImmunopharmaBiotechnology | SEC FORM 4 Bought | $1,3301,000 at $1.33 | filing |
| 7 Oct 2025filed 29 Apr 2026 | ESLA Estrella ImmunopharmaBiotechnology | SEC FORM 4 Bought | $1,3301,000 at $1.33 | filing |
| 22 Sep 2025filed 29 Apr 2026 | ESLA Estrella ImmunopharmaBiotechnology | SEC FORM 4 Bought | $1,1601,000 at $1.16 | filing |
| 22 Sep 2025filed 29 Apr 2026 | ESLA Estrella ImmunopharmaBiotechnology | SEC FORM 4 Bought | $1,1601,000 at $1.16 | filing |
| 11 Sep 2025filed 29 Apr 2026 | ESLA Estrella ImmunopharmaBiotechnology | SEC FORM 4 Bought | $104100 at $1.04 | filing |
| 11 Sep 2025filed 29 Apr 2026 | ESLA Estrella ImmunopharmaBiotechnology | SEC FORM 4 Bought | $104100 at $1.04 | filing |
| 30 Oct 2024filed 14 Feb 2025 | ESLA Estrella Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —490,796 | filing |
| 30 Oct 2024filed 14 Feb 2025 | ESLA Estrella Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —509,204 | filing |
| 30 Aug 2024filed 16 Sep 2024 | Denali Capital Acquisitionoption or derivative | SEC FORM 4 Code S | —500,000 | filing |
| 21 May 2022filed 24 May 2022 | Denali Capital Acquisitionoption or derivative | SEC FORM 4 Code D | —93,750 | filing |
| 11 Apr 2022filed 13 Apr 2022 | Denali Capital Acquisition | SEC FORM 4 Bought | $5.1M510,000 at $10.00 | filing |
News
Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion PhaseESLA · wallstreet-online.de · 15 Oct 2026
0 headlines in the last 90 days name Jiandong Xu; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.